Healthcare Quality and Information Healthcare Quality and Information Due to confusion between Ortho-McNeil's Reminyl (indicated for Alzheimer's disease) and Sanofi-Aventis' Amaryl (indicated for diabetes), Ortho-McNeil will now market Reminyl under the new trade name Razadyne. In addition, the extended release formulation (approved in December 2004) will be marketed as Razadyne ER. The immediate release formulation, Razadyne, will be available in pharmacies beginning July 2005, and the extended release formulation, Razadyne ER, will be available mid-May 2005. During review of transfer orders, a pharmacist noticed that a patient had been receiving Amaryl instead of Reminyl for four days. Upon admission, the patient was already in a hypoglycemic state and after receiving the Amaryl became severely hypoglycemic. Fortunately, the patient returned to normal with no permanent harm. It was discovered that the physician's order was illegible and the order was mistaken for Amaryl. The medication administration record (MAR) stated Reminyl, but the nurses did not notice that the drug name on the medication label dispensed was Amaryl.
